Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | F10 | P00742 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4413305 | 0.91 | L3MBTL1 (0.55) | FAAHMAPTPOLBL3MBTL1NPC1 | |
| SCHEMBL4425283 | 0.90 | MAPT (0.48) | FAAHMAPTPOLBL3MBTL1NPC1 | |
| SCHEMBL4414134 | 0.88 | ALDH1A1 (0.49) | FAAHMAPTL3MBTL1NPC1RAB9A | |
| SCHEMBL4412000 | 0.87 | ABL1 (0.52) | MAPTEPHX2L3MBTL1NPC1RAB9A | |
| SCHEMBL2167688 | 0.86 | L3MBTL1 (0.48) | FAAHMAPTL3MBTL1NPC1RAB9A | |
| SCHEMBL4415858 | 0.85 | FAAH (0.42) | FAAHMAPTPOLBEPHX2L3MBTL1 | |
| SCHEMBL4424930 | 0.84 | L3MBTL1 (0.45) | MAPTPOLBL3MBTL1NPC1RAB9A | |
| SCHEMBL4423658 | 0.83 | NPC1 (0.50) | FAAHMAPTL3MBTL1NPC1RAB9A | |
| SCHEMBL4413542 | 0.83 | MCHR1 (0.55) | FAAHMAPTL3MBTL1NPC1RAB9A | |
| SCHEMBL4415238 | 0.83 | HIF1A (0.52) | MAPTPOLBL3MBTL1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1680124-B1 | BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS | PFIZER PROD INC (US) | 2017-05-31 | — | — | EP | claimed |
| EP-1680124-A4 | BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS | PFIZER PROD INC (US) | 2009-05-13 | — | — | EP | claimed |
| JP-2007508374-A | — | — | 2007-04-05 | — | — | JP | claimed |
| EP-1680124-A2 | BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS | Pfizer Products Incorporated (US) | 2006-07-19 | — | — | EP | claimed |
| US-20050096375-A1 | Bicyclic [3.1.0] derivatives as glycine transporter inhibitors | PFIZER INC. | 2005-05-05 | — | — | US | claimed |
| WO-2005037216-A2 | BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS | PFIZER PRODUCTS INC. (US) | 2005-04-28 | — | — | WO | claimed |
| EP-1680124-B1 | BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS | PFIZER PROD INC (US) | 2017-05-31 | — | — | EP | disclosed |
| US-7473787-B2 | Bicyclic [3.1.0] derivatives as glycine transporter inhibitors | PFIZER INC (US) | 2009-01-06 | — | — | US | disclosed |
| US-20050096375-A1 | Bicyclic [3.1.0] derivatives as glycine transporter inhibitors | PFIZER INC. | 2005-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096375-A1 | Bicyclic [3.1.0] derivatives as glycine transporter inhibitors | SLC6A5, SLC1A5, SLC6A3 | FAAH 2866/4885MAPT 1368/4885POLB 2927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.